Facilitatory effects of fetuin-A on atherosclerosis

Atherosclerosis

Volumn 246, Issue , 2016, Pages 344-351

  Naito, Chisato ^a   Hashimoto, Mio ^a   Watanabe, Kaho ^a   Shirai, Remina ^a   Takahashi, Yui ^a   Kojima, Miho ^a   Watanabe, Rena ^a   Sato, Kengo ^a   Iso, Yoshitaka ^b   Matsuyama, Taka aki ^c   Suzuki, Hiroshi ^b   Ishibashi Ueda, Hatsue ^c   Watanabe, Takuya ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Atherosclerosis; Endothelial cell; Extracellular matrix; Fetuin A; Macrophage; Restenosis; Vascular smooth muscle cell

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ABC TRANSPORTER A1; BETA ACTIN; CD36 ANTIGEN; CHOLESTEROL ACYLTRANSFERASE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FETUIN A; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PARTHENOLIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B BETA; SARACATINIB; AHSG PROTEIN, HUMAN; AHSG PROTEIN, RAT; AUTACOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; DISEASE COURSE; DOWN REGULATION; EXTRACELLULAR MATRIX; FOAM CELL; FOGARTY CATHETER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MONOCYTE; NONHUMAN; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RESTENOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT; THIN LAYER CHROMATOGRAPHY; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; 3T3-L1 CELL LINE; ADULT; ANIMAL; CAROTID ARTERY INJURY; CELL MOTION; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HELA CELL LINE; LLC PK1 CELL LINE; METABOLISM; MOUSE; PATHOLOGY; PIG; SMOOTH MUSCLE CELL; TIME FACTOR; YOUNG ADULT;

3T3-L1 CELLS; ADULT; ALPHA-2-HS-GLYCOPROTEIN; ANIMALS; CAROTID ARTERIES; CAROTID ARTERY INJURIES; CELL MOVEMENT; CELL PROLIFERATION; CORONARY ARTERY DISEASE; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX; FOAM CELLS; HELA CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION MEDIATORS; LLC-PK1 CELLS; MALE; MICE; MONOCYTES; MYOCYTES, SMOOTH MUSCLE; PLAQUE, ATHEROSCLEROTIC; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SWINE; TIME FACTORS; YOUNG ADULT;

EID: 84956655746     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.01.037     Document Type: Article

References (50)

1. Ross R., Agius L. The process of atherogenesis-cellular and molecular interaction: from experimental animal models to humans. Diabetologia 1992, 35(Suppl. 2):S34-S40.
2. Allahverdian S., Pannu P.S., Francis G.A. Contribution of monocyte-derived macrophages and smooth muscle cells to arterial foam cell formation. Cardiovasc. Res. 2012, 95:165-172.
3. Denecke B., Gräber S., Schäfer C., Heiss A., Wöltje M., Jahnen-Dechent W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem. J. 2003, 376:135-145.
4. Jialal I., Devaraj S., Bettaieb A., Haj F., Adams-Huet B. Increased adiose tissue secretion of fetuin-A, lipopolysaccharide-binding protein and high-mobility group box protein 1 in metabolic syndrome. Atherosclerosis 2015, 241:130-137.
5. Reynolds J.L., Skepper J.N., McNair R., Kasama T., Gupta K., Weissberg P.L., Jahnen-Dechent W., Shanahan C.M. Multifunctional roles for serum protein fetuin-A in inhibition of human vascular smooth muscle cell calcification. J. Am. Soc. Nephrol. 2005, 16:2920-2930.
6. Singh M., Sharma P.K., Garg V.K., Mondal S.C., Singh A.K., Kumar N. Role of fetuin-A in atherosclerosis associated with diabetic patients. J. Pharm. Pharmacol. 2012, 64:1703-1708.
7. Mori K., Emoto M., Inaba M. Fetuin-A and the cardiovascular system. Adv. Clin. Chem. 2012, 56:175-195.
8. Chatterjee P., Seal S., Mukherjee S., Kundu R., Mukherjee S., Ray S., Mukhopadhyay S., Majumdar S.S., Bhattacharya S. Adipocyte fetuin-A contributes to macrophage migration into adipose tissue and polarization of macrophages. J. Biol. Chem. 2013, 288:28324-28330.
9. Hennige A.M., Staiger H., Wicke C., Machicao F., Fritsche A., Häring H.U., Stefan N. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One 2008, 3:e1765.
10. Siegel-Axel D.I., Ullrich S., Stefan N., Rittig K., Gerst F., Klingler C., Schmidt U., Schreiner B., Randrianarisoa E., Schaller H.E., Stock U.A., Weigert C., Königsrainer A., Häring H.U. Fetuin-A influences vascular cell growth and production of proinflammatory and angiogenic proteins by human perivascular fat cells. Diabetologia 2014, 57:1057-1066.
11. 2-HS-glycoprotein) opsonizes cationic macrophage deactivating molecules. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14429-14434.
12. 2-HS glycoprotein is a transforming growth factor-β type II receptor mimic and cytokine antagonist. J. Biol. Chem. 1996, 271:12755-12761.
13. 2-HS glycoprotein is down-regulated by cytokines in hepatoma HepG2 cells. FEBS Lett. 1988, 241:191-194.
14. Ray S., Lukyanov P., Ochieng J. Members of the cystatin superfamily interact with MMP-9 and protect it from autolytic degradation without affecting its gelatinolytic activities. Biochim. Biophys. Acta 2003, 1652:91-102.
15. Sun Z.L., Xie Q.Y., Guo G.L., Ma K., Huang Y.Y. Serum fetuin-A levels in patients with cardiovascular disease: a meta-analysis. Biomed. Res. Int. 2014, 2014:691540.
16. Szeberin Z., Fehérvári M., Krepuska M., Apor A., Rimely E., Sarkadi H., Széplaki G., Prohászka Z., Kalabay L., Acsády G. Serum fetuin-A levels inversely correlate with the severity of arterial calcification in patients with chronic lower extremity atherosclerosis without renal disease. Int. Angiol. 2011, 30:474-480.
17. Mori K., Ikari Y., Jono S., Emoto M., Shioi A., Koyama H., Shoji T., Ishimura E., Inaba M., Hara K., Nishizawa Y. Fetuin-A is associated with calcified coronary artery disease. Coron. Artery Dis. 2010, 21:281-285.
18. Ix J.H., Katz R., de Boer I.H., Kestenbaum B.R., Peralta C.A., Jenny N.S., Budoff M., Allison M.A., Criqui M.H., Siscovick D., Shlipak M.G. Fetuin-A is inversely associated with coronary artery calcification in community-living persons: the multi-ethnic study of atherosclerosis. Clin. Chem. 2012, 58:887-895.
19. Weikert C., Stefan N., Schulze M.B., Pischon T., Berger K., Joost H.G., Häring H.U., Boeing H., Fritsche A. Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. Circulation 2008, 118:2555-2562.
20. Bilgir O., Kebapcilar L., Bilgir F., Bozkaya G., Yildiz Y., Pinar P., Tastan A. Decreased serum fetuin-A levels are associated with coronary artery diseases. Intern. Med. 2010, 49:1281-1285.
21. Vörös K., Gráf L., Prohászka Z., Gráf L., Szenthe P., Kaszás E., Böröcz Z., Cseh K., Kalabay L. Serum fetuin-A in metabolic and inflammatory pathways in patients with myocardial infarction. Eur. J. Clin. Investig. 2011, 41:703-709.
22. Zhao Z.W., Lin C.G., Wu L.Z., Luo Y.K., Fan L., Dong X.F., Zheng H. Serum fetuin-A levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes. Biomarkers 2013, 18:160-164.
23. Lim P., Montereau S., Simon T., Gallet R., Probst V., Ferrieres J., Gueret P., Danchin N. Usefulness of fetuin-A and C-reactive protein concentrations for prediction of outcome in acute coronary syndromes (from the French registry of acute ST-Elevation Non-ST-Elevation myocardial infarction [FAST-MI]). Am. J. Cardiol. 2013, 111:31-37.
24. Sun Q., Jiménez M.C., Townsend M.K., Townsend M.K., Rimm E.B., Manson J.E., Albert C.M., Rexrode K.M. Plasma levels of fetuin-A and risk of coronary heart disease in US women: the Nurses' health Study. J. Am. Heart Assoc. 2014, 3:e000939.
25. Coker-Gurkan A., Coskun D., Arisan E.D., Obakan P., Soylu O., Unsal N.P. Fetuin-A 742 (C/T) and 766 (C/G) polymorphic sites are associated with increased risk of myocardial infarction in older patients (≥40 years of age). Mol. Med. Rep. 2015, 12:1356-1362.
26. Watanabe T., Nishio K., Kanome T., Matsuyama T., Koba S., Sakai T., Sato K., Hongo S., Nose K., Ota H., Kobayashi Y., Katagiri T., Shichiri M., Miyazaki A. Impact of salusin-α and -β on human macrophage foam cell formation and coronary atherosclerosis. Circulation 2008, 117:638-648.
27. 1 on macrophage foam cell formation and atherosclerosis. Circ. Res. 2009, 105:500-510.
28. Konii H., Sato K., Kikuchi S., Okiyama H., Watanabe R., Hasegawa A., Yamamoto K., Itoh F., Hirano T., Watanabe T. Stimulatory effects of cardiotrophin 1 on atherosclerosis. Hypertension 2013, 62:942-950.
29. Hasegawa A., Sato K., Shirai R., Watanabe R., Yamamoto K., Watanabe K., Nohtomi K., Hirano T., Watanabe T. Vasoprotective effects of urocortin 1 against atherosclerosis in vitro and in vivo. PLoS One 2014, 9:e110866.
30. Watanabe T., Suguro T., Kanome T., Sakamoto Y., Kodate S., Hagiwara T., Hongo S., Hirano T., Adachi M., Miyazaki A. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 2005, 46:738-744.
31. Watanabe K., Watanabe R., Konii H., Shirai R., Sato K., Matsuyama T., Ishibashi-Ueda H., Koba S., Kobayashi Y., Hirano T., Watanabe T. Counteractive effects of omentin-1 against atherogenesis. Cardiovasc Res. 2015, (in press).
32. Mukhopadhyay S., Mondal S.A., Kumar M., Dutta D. Proinflammatory and antiinflammatory attributes of fetuin-A: a novel hepatokine modulating cardiovascular and glycemic outcomes in metabolic syndrome. Endocr. Pract. 2014, 20:1345-1351.
33. Wang H., Li W., Zhu S., Li J., D'Amore J., Ward M.F., Yang H., Wu R., Jahnen-Dechent W., Tracey K.J., Wang P., Sama A.E. Peripheral administration of fetuin-A attenuates early cerebral ischemic injury in rats. J. Cereb. Blood Flow. Metab. 2010, 30:493-504.
34. Merx M.W., Schäfer C., Westenfeld R., Brandenburg V., Hidajat S., Weber C., Ketteler M., Jahnen-Dechent W. Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. J. Am. Soc. Nephrol. 2005, 16:3357-3364.
35. Westenfeld R., Schäfer C., Krüger T., Haarmann C., Schurgers L.J., Reutelingsperger C., Ivanovski O., Drueke T., Massy Z.A., Ketteler M., Floege J., Jahnen-Dechent W. Fetuin-A protects against atherosclerotic calcification in CKD. J. Am. Soc. Nephrol. 2009, 20:1264-1274.
36. 2-Heremans-Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. Atherosclerosis 2007, 195:110-115.
37. Rittig K., Thamer C., Haupt A., Machann J., Peter A., Balletshofer B., Fritsche A., Haring H.U., Stefan N. High plasma fetuin-A is associated with increased carotid intima-media thickness in a middle-aged population. Atherosclerosis 2009, 207:341-342.
38. Tuttolomondo A., Di Raimondo D., Di Sciacca R., Casuccio A., Bivona G., Bellia C., Barreca L., Serio A., D'Aguanno G., Ciaccio M., Licata G., Pinto A. Fetuin-A and CD40 L plasma levels in acute ischemic stroke: differences in relation to TOAST subtype and correlation with clinical and laboratory variables. Atherosclerosis 2010, 208:290-296.
39. Wang A.Y., Woo J., Lam C.W., Wang M., Chan I.H., Gao P., Lui S., Li P.K., Sanderson J.E. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol. Dial. Transpl. 2005, 20:1676-1685.
40. Dogru T., Genc H., Tapan S., Aslan F., Ercin C.N., Ors F., Kara M., Sertoglu E., Karslioglu Y., Bagci S., Kurt I., Sonmez A. Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. Clin. Endocrinol. Oxf. 2013, 78:712-717.
41. Aydin F.N., Agilli M., Cayci T., Kurt Y.G. The effect of serum fetuin-A on atherosclerosis in hemodialysis patients. Saudi. J. Kidney Dis. Transpl. 2015, 26:370-371.
42. Koluman B.U., Mutluay R., Derici U.B., Arinsoy T., Senlik Z., Bahar B., Sancak B., Oktan S.O., Sindel S. Association between osteoprotegerin, fetuin-A, carotid intima media thickness, and urinary albumin excretion in type 2 diabetes. Clin. Nephrol. 2013, 80:9-16.
43. Ozturk K., Uygun A., Guler A.K., Demirci H., Ozdemir C., Cakir M., Sakin Y.S., Turker T., Sari S., Demirbas S., Karslioğlu Y., Saglam M. Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men. Atherosclerosis 2015, 240:380-386.
44. Beddhu S., Kaysen G.A., Yan G., Sarnak M., Agodoa L., Ornt D., Cheung A.K. Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am. J. Kidney Dis. 2002, 40:721-727. HEMO Study Group.
45. Joki N., Hase H., Tanaka Y., Takahashi Y., Saijyo T., Ishikawa H., Inishi Y., Imamura Y., Hara H., Tsunoda T., Nakamura M. Relationship between serum albumin level before initiating haemodialysis and angiographic severity of coronary atherosclerosis in end-stage renal disease patients. Nephrol. Dial. Transpl. 2006, 21:1633-1639.
46. Wu C.Y., Martel J., Young D., Young J.D. Fetuin-A/albumin-mineral complexes resembling serum calcium granules and putative nanobacteria: demonstration of a dual inhibition-seeding concept. PLoS One 2009, 4:e8058.
47. Smith E.R., Hanssen E., McMahon L.P., Holt S.G. Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage. PLoS One 2013, 8:e60904.
48. Dautova Y., Kozlova D., Skepper J.N., Epple M., Bootman M.D., Proudfoot D. Fetuin-A and albumin alter cytotoxic effects of calcium phosphate nanoparticles on human vascular smooth muscle cells. PLoS One 2014, 9:e97565.
49. Leosco D., Fineschi M., Pierli C., Fiaschi A., Ferrara N., Bianco S., Longobardi G., Pisani E., Bravi A., Rengo F. Intracoronary serotonin release after high-pressure coronary stenting. Am. J. Cardiol. 1999, 84:1317-1322.
50. Cartellieri S., Hamer O., Helmholz H., Niemeyer B. One-step affinity purification of fetuin from fetal bovine serum. Biotechnol. Appl. Biochem. 2002, 35:83-89.